医渡科技2024年度报告
公司資料2核心財務及營運數據4董事長致辭6業務回顧10管理層討論及分析19董事會報告25董事及高級管理層39環境、社會及管治報告44其他資料117企業管治報告132獨立核數師報告151合併綜合收益表159合併資產負債表161合併權益變動表163合併現金流量表164合併財務報表附註165財務概要260釋義261 98 18819 Suite#4–210, Governors Square 23Lime Tree Bay AvenuePO Box 32311Grand Cayman KY1-1209, Cayman Islands 22 香港及美國法律•1523 中國法律 1C19100738 開曼群島法律 1826 183171712–1716 Maples Fund Services (Cayman) LimitedPO Box 1093, Boundary HallCricket SquareGrand Cayman KY1-1102, Cayman Islands 83One Bay East 8E1 28B1 2158 www.yidutechgroup.com 2024 市場地位領先 •3 •32142465•41227.6 1(i)(ii)2345 AI-YiduCore 疾病知識圖譜基本涵蓋 疾病領域：和 AIYiduCore •5,000Token6B13B 70B•••20245AIMedBench 城市網絡：43監管機構和政策制定者 覆蓋頂級醫院102家，醫院2,500+家 保險智能模型和算法累計落地412 AIAIYiduCore 20242024 AIYiduCore 8.042.1%65.0%64.8%229.550.4%2024331 2024331102436–122650%151.1%75.4%(RWE) 2024331MNC202420%30% AI AI20243311050 AI5000TOKEN6B13B70B20245MedBench 董事長致辭（續） YiduCore 202433125004380127.6YiduCore YiduCore2+3500724 AI202433141290%20231560035% AI 2024627 2024331 (AI)AIAIAIAIAI 2024807.1202334.1%42.1%8.02023632.4221.265.0%229.550.4%20243313,409.93,522.0 AIYiduCore5,000Token6B13B 70B20245AIMedBenchYiduCore2024331YiduCore1050YiduCore 業務回顧（續） 2024331102432,50012210151.1%60.6%201627.6 YiduCore YiduCoreAIYiduCoreYiduCoreYiduCore5,000Token6B13B 70B YiduCore1050100,00080AI10AI 20245AIMedBenchYiduCore YiduCore500724AI 313.641.4%202433114102943 AIYiduEywaAI6–122–650% 業務回顧（續） 20 iGCP8 AI 402,00050408 AI 324.028.1%14.632.1%202433110151.1%75.4%201632124620243311347 (DCT)DCTIIIDCT2023DCTDCT (RWE)2024331MNC20243318 業務回顧（續） YiduCore2I 9 AI169.548.7%58.1%17.4 202433141290%202315AIYiduCore635%1,0001,3002024202420%30% 80%AI50%–70% YiduCore4,00011%12% 202433127.6 業務回顧（續） AI(i)AIYiduCore(ii)(iii)(iv) (i)(ii)(iii) YiduCore(i)(ii)RWE(iii)(iv) (i)(ii)(iii) AI 2023331804.70.3%2024331807.1 2023331221.941.4%2024331313.6COVID-19 2023331252.928.1%2024331324.0COVID-19 2023331329.948.7%2024331169.5 2023331530.211.8%2024331467.6202320243318.05.5 2023331126.040.2%2024331176.7(i)65.492.0(ii)59.378.63.83.5 2023331208.75.4%2024331220.0(i)113.3147.1(ii)88.465.72.11.2 管理層討論及分析（續） 2023331195.563.7%202433170.9(i)171.554.7(ii)22.913.52.10.8 20232024331274.5339.434.1%42.1% 202333143.2%202433143.7% 202333117.5%202433132.1%2024331 202333140.7%202433158.1% 2023331271.623.1%2024331208.9(i)165.0132.917.113.5(ii)93.764.6 202333133.8%202433125.9% 管理層討論及分析（續） 2023331232.026.2%2024331171.3182.5123.147.625.7 202333128.8%202433121.2% 2023331342.532.0%2024331232.9259.7152.426.314.0 202333142.6%202433128.9% 2023331630.065.1%2024331219.9 20233313.420243310.05 2023331632.465.0%2024331221.2 — 管理層討論及分析（續） (i)(ii) 20232024331 (1) (2) (3) 2024331202320243313,522.03,409.9 管理層討論及分析（續） 20221028Marvelous Panda Inc.YD Capital I L.P.40.040%20243315.6(i)(ii)(iii) 331 2024331 2024331 2024331–437.0% 2024331202433194.84.42023331300.184.6 20232024331 20243312023331 33120233312.3 管理層討論及分析（續） 2024331256.62023331284.0Marvelous Panda Inc.YD Capital I L.P. 20243319024551033442024331 2024331566.32023331777.72023825 ESG 331 2024331 執行董事 非執行董事 獨立非執行董事 3943 20141292021115 (AI) 5 159 董事會報告（續） 6225102435 •••AI•••••• ESG 董事會報告（續） 20243314014A14A 合約安排 202081880.5%202360.5%15.6%202320.8% 董事會報告（續） (i)(ii)(iii) (1)99%1% (2)99%1% (3)99%1% (4)51%49% (5)(6)(7)(8)(9)(10)(11)(i)(ii)(iii) 7681 ••••••• 董事會報告（續） 2020818 (a)(b)(c) 董事會報告（續） 202081810 2020818 2020109202092920209292020930 董事會報告（續） 2020818 (i)(ii)(iii)(iv)(v) 248266 14A 14A14A (i)14A.105(ii)14A.53(iii)14A.52 (a) (b) (c) (d)(i)(ii)(iii) (e) 董事會報告（續） (i)(ii)(iii)(iv)(v)(vi) (i)(ii)(iii)(iv) 董事會報告（續） 86.510.7%262.032.5% 5% (i)IT(ii) 34.47.0%146.229.9% 5% 12 16 董事會報告（續） 28 2.9 20243312024331 2024331 1632942 23 董事會報告（續） 3.25C1 31119130 439 董事會報告（續） 50.743 8.10 13.2013.2113.22 2024627 (1) 執行董事 40 Credit Suisse First BostonCredit Suisse2005720073Global Infrastructure Partners LLP2006112007620077200812(Deutsche Bank AG)2011120122Credit Suisse First BostonGlobal Infrastructure Partners LLP20193 20121020057 董事及高級管理層（續） 40202322015102018320191— 20151020156201510UCWeb20135201562008720135 2008720057 閆45201712 20171220067201711 100ACM(SIGKDD)ACM(SIGIR)(WWW)IEEEIEEE 2018122018 2006720017 45202322001212022IRIRSC 2022–20232023ESG201512201822018220195OFO (HK) Limited2019520247301305 非執行董事 5420216252006201820116202319601998—1991INSEAD 獨立非執行董事 5620211201722020820014201721997420014200710201912(BAAI)(2021–2023)202010(AIR) 董事及高級管理層（續） 169300(SIGIR2011)(WWW2008)2011(IEEEFellow)2023(ACM Fellow)20171997619941219906 4620211202356600201811SciClone Pharmaceuticals Group202122002720181120137201811 2004 2001719987 602021120087201412015620032007•19988200311995919987•2017820239688399 30HIVCOVID-19—200 20152008HIV/AIDS2016 719857 — 20232141—— 20201016999266693D Medicines Inc.1244314179520111020157 13.51B(1) 65 108110 1.ESG發展歷程 1.1ESG (ESG) • • AI •
